Ephedrine amount in labeling should be required by FDA final rule, CRN suggests.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE WEIGHT LOSS CLAIMS COMPLETE BAN "INAPPROPRIATE," CRN maintains in Dec. 1 comments on FDA's June 4 proposed rule on dietary supplements containing ephedrine alkaloids. The proposed rule seeks to ban ephedrine-containing dietary supplements from recommending more than seven days of concurrent use ("The Tan Sheet" June 9. pp. 20-23). "Regarding the weight loss claim, CRN believes a complete prohibition would be inappropriate," the Council for Responsible Nutrition states. The comment period ended Dec. 2.